Expertise in
24
conditions

Dr. Ding Wang

Oncology
Office
4100 John R St Fl 4, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 4 Trials
37 Years of Experience
Expertise in
24
conditions
Office
4100 John R St Fl 4, 
Detroit, MI 

Overview

Ding Wang is an Oncologist practicing medicine in Detroit, Michigan. He has been practicing medicine for over 37 years.

Dr. Wang is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Melanoma, Astrocytoma, Squamous Cell Skin Carcinoma, Bone Marrow Aspiration, and Nephrectomy.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 94 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
4100 John R St Fl 4, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

94 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Atezolizumab, Cisplatin, Pemetrexed Disodium
Study Phase: Phase 1
View 6 Less Clinical Trials

4 Total Publications

A Case of Symptomatic Cerebral Radiation Necrosis for an Extra-Cranial Neoplasm from Conventional Radiotherapy With Concurrent Immunotherapy.
A Case of Symptomatic Cerebral Radiation Necrosis for an Extra-Cranial Neoplasm from Conventional Radiotherapy With Concurrent Immunotherapy.
Journal: Cureus
Published: June 17, 2021
Similar Doctors
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology
Referral may be required

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
31
conditions
Dr. Philip Philip
Oncology
Expertise in
31
conditions
Dr. Philip Philip
Oncology
Referral may be required

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Philip is an Oncologist practicing medicine in Detroit, Michigan. Dr. Philip is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreatectomy.

Expertise in
14
conditions
Dr. Elisabeth Heath
Oncology
Expertise in
14
conditions
Dr. Elisabeth Heath
Oncology
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
313-576-8715
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elisabeth Heath is an Oncologist practicing medicine in Detroit, Michigan. Dr. Heath is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Frequently Asked Questions about Dr. Ding Wang

How do I make an appointment with Dr. Ding Wang?

You can book an appointment with Dr. Ding Wang by calling their office at 800-527-6266. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ding Wang a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ding Wang is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ding Wang specialize in?

While Dr. Ding Wang is a Oncology, they have specific expertise in Melanoma, Astrocytoma, and Squamous Cell Skin Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ding Wang participate in research or clinical trials?

Yes. Dr. Ding Wang has published 4 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Ding Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ding Wang accept my insurance?

Dr. Ding Wang accepts most major insurance plans, including Humana. We recommend calling the office directly at 800-527-6266 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 90 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile